Healthcare
XOMA Royalty Corp.(XOMA)
Live Price
Offline$41.89
+0.41% today
1Y Change
+59.76%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $500.00M
- Revenue Growth
- +83.1%
- EPS Growth
- +192.7%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
XOMA Royalty Corp. (XOMA) is a Healthcare stock with a market cap of $500.00M and listed on NASDAQ. The stock last traded around $41.89 and up 59.8% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +83.1%, EPS growth of +192.7%, a dividend yield of 0.0%. What stands out right now is revenue +83.1%, EPS +192.7%, free cash flow +120.9% with operating margin 21.8% and ROIC 4.5%. Valuation already assumes a fairly strong business story at P/E 25.2 and price/sales 9.5. Stock Foundry combines XOMA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+83.1% vs +7.6% peer median
Operating Margin
Above sector median
+21.8% vs +19.4% peer median
P/E
Below sector median
25.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 12, 2026 with an EPS surprise of -10.5% and a revenue surprise of -11.4%.
The operating story is still moving forward
Revenue is running at +83.1% and EPS at +192.7%, with operating margin around 21.8%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 12, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | -10.5% | +0.1% | -0.5% | +0.0% |
2026 Mar 18, 2026 | +192.3% | +5.2% | +10.4% | +44.8% |
2025 Nov 12, 2025 | -1650.0% | -4.1% | -1.4% | -21.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XOMA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
XOMA Max Drawdown
-42.37%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for XOMA and SPY.
Company Overview
XOMA Royalty Corp.
NASDAQ Global Market
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
- Leadership
- Owen Hughes Jr.
- IPO Date
- Jun 6, 1986
- Employees
- 13
- Street Address
- 2200 Powell Street
- Mailing
- EmeryVille, CA, 94608
- Region
- EmeryVille, CA, US
- Reporting Currency
- USD
- Investor Line
- 510 204 7200
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 25.2
- EV/EBITDA
- 38.1
- Price/Sales
- 9.5
- Price/Book
- 7.1
Growth
- Revenue
- +83.1%
- EPS
- +192.7%
- Free Cash Flow
- +120.9%
Profitability
- Gross Margin
- 94.3%
- Operating Margin
- 21.8%
- Net Margin
- 56.4%
- ROE
- 30.2%
- ROIC
- 4.5%
Balance Sheet
- Debt/Equity
- 1.27
- Current Ratio
- 3.37
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.